Figure 1
From: An ACE2 Triple Decoy that neutralizes SARS-CoV-2 shows enhanced affinity for virus variants
Biolayer Interferometry (BLI) of ACE2-IgG1FC, ACE2-IgAFC, and mutant decoy binding to the spike receptor binding domain; and live virus neutralization. The (a) ACE2-IgG1FC decoy and (b) dimeric ACE2-IgAFC decoy fused via a J-chain are shown. BLI kinetics analysis of (c) 1:1 binding and (d) binding with avidity for the ACE2-IgG1FC decoy; (e) BLI binding with avidity for the ACE2-IgAFC decoy; (f) ACE2(T27Y)-IgG1FC, (g) ACE2(H34A)-IgG1FC, and (h) ACE2(T27Y/H34A)-IgG1FC decoys are shown with KD values. (i) Virus neutralization as percent for concentrations of decoy is shown with IC50s for ACE2(WT)-IgG1FC and ACE2(T27Y/H34A)-IgG1FC. Negative controls: media and higG1 (human IgG1).
